EDMONTON, April 9 /CNW/ - Cyplasin Biomedical, a specialty pharmaceutical company focused on hepatitis prevention and anti-viral therapies, has retained Investor Outreach Services ("IOS") as advisors to communicate its corporate development and strategic goals to the investment community.
Cyplasin has made significant strides recently and management believes that it is now appropriate to take the message of growth and future success to the investment community. Investor Outreach Services was chosen due to their focused experience in working with micro-capitalization companies and an extensive network of investor relations specialists." Commenting on the new relationship, Al Turano, Managing Director of IOS stated, "We look forward to effectively disseminating Cyplasin's corporate developments relating to the Company's hepatitis therapy products C-Virin and C-Peg products as well as the progress expected on the Cyplasin preventative vaccine against hepatitis C (HCV)." He went on to further state that "There are 250 million plus people worldwide infected with Hepatitis C, which is roughly equivalent to the population of the USA, which is a staggering amount of people when viewed in this perspective".
Garth Likes, President and CEO of Cyplasin stated, "We are happy to be able to attract a firm of IOS's calibre to our story and to participate with us in its development".
About: Cyplasin Biomedical is a public biopharmaceutical company focused on the commercialization of life-saving products targeted for sale in the multi-billion dollar global hepatitis C market.
Forward Looking Statements
This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this current report which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainty of financial estimates and projections, the competitive and regulatory environments, stock market conditions, unforeseen technical difficulties and our ongoing ability to operate a business and obtain financing. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.
Although we believe that our beliefs, plans, expectations and intentions contained in this current report are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our quarterly reports on Form 10-Q and our other periodic reports filed from time-to-time with the Securities and Exchange Commission pursuant to the Securities Exchange Act.
SOURCE CYPLASIN BIOMEDICAL LTD.
For further information: For further information: and inquiries CONTACT: Mr. Garth Likes, President/CEO, firstname.lastname@example.org, Suite 131, Advanced Technology Center, 9650-20th Avenue, Edmonton, Alberta, (780) 990-4539